Franklin Genomic Market Risk Adjusted Performance
| HELX Etf | | | USD 35.22 0.18 0.51% |
Franklin Genomic market-risk-adjusted-performance technical analysis lookup allows you to check this and other technical indicators for Franklin Genomic Advancements or any other equities. You can select from a set of available technical indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations and data normalization technicques. Please check also
Equity Screeners to view more equity screening tools
Franklin Genomic Advancements has current Market Risk Adjusted Performance of 0.0338.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | 0.0338 | |
| ER[a] | = | Expected return on investing in Franklin Genomic |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Franklin Genomic Market Risk Adjusted Performance Peers Comparison
Franklin Market Risk Adjusted Performance Relative To Other Indicators
Franklin Genomic Advancements is rated
below average in market risk adjusted performance as compared to similar ETFs. It is currently under evaluation in maximum drawdown as compared to similar ETFs reporting about
208.61 of Maximum Drawdown per Market Risk Adjusted Performance. The ratio of Maximum Drawdown to Market Risk Adjusted Performance for Franklin Genomic Advancements is roughly
208.61
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.